Acquisition by Link William J Phd of 27116 shares of Tarsus Pharmaceuticals subject to Rule 16b-3

TARS Stock  USD 48.24  1.84  3.97%   
Slightly above 56% of Tarsus Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Tarsus Pharmaceuticals stock suggests that many investors are alarmed at this time. Tarsus Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Tarsus Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Tarsus Pharmaceuticals Director. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Tarsus insider trading alert for acquisition of common stock by Link William J Phd, Director, on 30th of August 2024. This event was filed by Tarsus Pharmaceuticals with SEC on 2024-08-12. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Tarsus Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Tarsus Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Tarsus Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Tarsus Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Tarsus Pharmaceuticals Fundamental Analysis

We analyze Tarsus Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tarsus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tarsus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Operating Margin

Operating Margin Comparative Analysis

Tarsus Pharmaceuticals is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Tarsus Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tarsus Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Tarsus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Tarsus Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Tarsus Pharmaceuticals Related Equities

SLNOSoleno Therapeutics   5.77   
0%
100.0%
TILInstil Bio   5.61   
0%
97.0%
CAPRCapricor Therapeutics   4.67   
0%
80.0%
BPTHBio Path   2.50   
0%
43.0%
CTMXCytomX Therapeutics   2.30   
0%
39.0%
ASMBAssembly Biosciences   2.17   
0%
37.0%
ACHLAchilles Therapeutics   0.93   
16.0%
0%
CRNXCrinetics Pharmaceuticals   1.70   
29.0%
0%
MBRXMoleculin Biotech   3.53   
61.0%
0%

Additional Tools for Tarsus Stock Analysis

When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.